44 related articles for article (PubMed ID: 38531118)
1. The emicizumab-bridged ternary complex with activated factor IX and factor X evaluated by fluorescence resonance energy transfer.
Oda A; Takeyama M; Kitazawa T; Nogami K
Thromb Res; 2024 May; 237():108-111. PubMed ID: 38579512
[No Abstract] [Full Text] [Related]
2. Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays.
Adamkewicz JI; Kiialainen A; Paz-Priel I
Int J Lab Hematol; 2020 Apr; 42(2):e71-e75. PubMed ID: 31670901
[No Abstract] [Full Text] [Related]
3. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.
Teranishi-Ikawa Y; Soeda T; Koga H; Yamaguchi K; Kato K; Esaki K; Asanuma K; Funaki M; Ichiki M; Ikuta Y; Ito S; Joyashiki E; Komatsu SI; Muto A; Nishimura K; Okuda M; Sanada H; Sato M; Shibahara N; Wakabayashi T; Yamaguchi K; Matsusaki A; Sampei Z; Shiraiwa H; Konishi H; Kawabe Y; Hattori K; Kitazawa T; Igawa T
J Thromb Haemost; 2024 Feb; 22(2):430-440. PubMed ID: 37940048
[TBL] [Abstract][Full Text] [Related]
4. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
[TBL] [Abstract][Full Text] [Related]
5. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
[TBL] [Abstract][Full Text] [Related]
6. Antithrombin exhibits anticoagulant effects on the emicizumab-based engineered bispecific antibody (NXT007)-mediated blood coagulation.
Nakajima Y; Ogiwara K; Inaba K; Kitazawa T; Nogami K
Thromb Res; 2024 May; 237():14-17. PubMed ID: 38531118
[No Abstract] [Full Text] [Related]
7. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Lenting PJ; Denis CV; Christophe OD
Blood; 2017 Dec; 130(23):2463-2468. PubMed ID: 29042366
[TBL] [Abstract][Full Text] [Related]
8. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
Kitazawa T; Shima M
Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
[TBL] [Abstract][Full Text] [Related]
9. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
Yada K; Nogami K
Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
[TBL] [Abstract][Full Text] [Related]
10. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
[TBL] [Abstract][Full Text] [Related]
11. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
Díaz-Ricart M; Isola IM; Escolar G
Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]